HYDROA VACCINIFORME-LIKE LYMPHOPROLIFERATIVE DISORDER
Clinical trials for HYDROA VACCINIFORME-LIKE LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new HYDROA VACCINIFORME-LIKE LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for HYDROA VACCINIFORME-LIKE LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug DR-01 targets rare blood cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-phase trial.
Matched conditions: HYDROA VACCINIFORME-LIKE LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
Massive T-Cell lymphoma database aims to unlock better treatments
Knowledge-focused Recruiting nowThis study is creating a large database of information from 1,000 people with T-cell lymphoma. Researchers will collect medical records and tumor samples to learn more about the disease and how to improve care. No new treatments are being tested; the goal is to gather data for fu…
Matched conditions: HYDROA VACCINIFORME-LIKE LYMPHOPROLIFERATIVE DISORDER
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC